Calidi Biotherapeutics vs PharmaCyte Biotech
CLDI and PMCB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLDI and PMCB compare
PharmaCyte Biotech is the larger company, worth 45 times as much as Calidi Biotherapeutics ($71.7M against $1.6M).
PharmaCyte Biotech scores higher on the StockData Score (6 against 2 for Calidi Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLDI | PMCB |
|---|---|---|
| Size and price | ||
| Market cap | $1.6M | $71.7M |
| Share price | $0.622 | $6.68 |
| Change, 1 year | −97.4% | −58.7% |
| Change, 5 years | −100.0% | −86.5% |
| Beta (5Y) | 0.50 | 3.47 |
| Employees | – | 2 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.0× (better) | 2.6× |
| Growth | ||
| Net income growth (TTM) | – | −163% |
| Profitability | ||
| Return on equity | −374% | −48.9% (better) |
| Return on invested capital | – | −23.5% |
| Financial health | ||
| Debt / equity | 0.41 (better) | 0.00 |
| Interest coverage | −252.2× | – |
| Current ratio | 1.27 | 40.30 (better) |
| Altman Z-score | −48.70 | 2.44 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.56% |
| Shareholder yield | 0.00% | 0.56% (better) |
| Ownership | ||
| Held by institutions | – | 7.1% |
| Held by insiders | 58.4% | 7.1% |
| Insider net buying, 12 months | −$1.2K | $129K (better) |
| Short interest, % of float | – | 0.51% |
Go deeper
- CLDI stock overview
- CLDI income statement
- CLDI valuation and score
- PMCB stock overview
- PMCB income statement
- PMCB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.